CN115212254A - 头花蓼在制备抗肝损伤药物方面的应用 - Google Patents
头花蓼在制备抗肝损伤药物方面的应用 Download PDFInfo
- Publication number
- CN115212254A CN115212254A CN202210976424.6A CN202210976424A CN115212254A CN 115212254 A CN115212254 A CN 115212254A CN 202210976424 A CN202210976424 A CN 202210976424A CN 115212254 A CN115212254 A CN 115212254A
- Authority
- CN
- China
- Prior art keywords
- liver
- liver injury
- polygonum capitatum
- agent
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 72
- 241000764065 Persicaria capitata Species 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title description 5
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 208000006454 hepatitis Diseases 0.000 claims abstract description 5
- 231100000354 acute hepatitis Toxicity 0.000 claims abstract description 4
- 231100000234 hepatic damage Toxicity 0.000 claims description 12
- 230000008818 liver damage Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 abstract description 37
- 210000004185 liver Anatomy 0.000 abstract description 29
- 229940079593 drug Drugs 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 16
- 231100000439 acute liver injury Toxicity 0.000 abstract description 15
- 210000003494 hepatocyte Anatomy 0.000 abstract description 15
- 230000002633 protecting effect Effects 0.000 abstract description 10
- 102000013691 Interleukin-17 Human genes 0.000 abstract description 9
- 108050003558 Interleukin-17 Proteins 0.000 abstract description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 230000007850 degeneration Effects 0.000 abstract description 5
- 230000008595 infiltration Effects 0.000 abstract description 4
- 238000001764 infiltration Methods 0.000 abstract description 4
- 230000017074 necrotic cell death Effects 0.000 abstract description 4
- 235000019441 ethanol Nutrition 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 8
- 210000005229 liver cell Anatomy 0.000 description 8
- 235000017700 silymarin Nutrition 0.000 description 8
- 229960004245 silymarin Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- -1 alkyl glycosides Chemical class 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- NDHYXZCDTGNTSM-UHFFFAOYSA-N trichloro(trichloromethylperoxy)methane Chemical compound ClC(Cl)(Cl)OOC(Cl)(Cl)Cl NDHYXZCDTGNTSM-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及医药技术领域,具体是头花蓼在制备抗肝损伤药物方面的应用。本发明通过研究,发现了头花蓼对急性肝损伤具有明显的保护效果以及剂量依赖,有效的显著保护了四氯化碳造成的急性肝损伤;还能有效减轻肝细胞坏死程度,降低肝细胞炎症浸润程度,减少肝细胞空泡样变性,有明显保护肝损伤的效果;并且可通过抑制炎症因子TNF‑α、IL‑17与IL‑1β的水平,从而发挥保肝作用。头花蓼醇提取物能够用于制备抗肝损伤药物,为治疗急性肝炎肝损伤提供了全新的、安全有效的天然药物,可以得到一系列以其为基础的新型保肝药物。
Description
技术领域
本发明涉及医药技术领域,具体是头花蓼在制备抗肝损伤药物方面的应用。
背景技术
肝脏是人体内脏中最大的实质性器官,在人体的代谢活动中发挥着重要作用,绝大多数摄入体内的物质都要通过肝脏的代谢转化。除此之外,肝脏还具有分泌胆汁、凝血、解毒、免疫和吞噬等多种重要的生理功能,所以在维持机体生命活动中发挥着至关重要的作用。诸多因素都可以造成肝脏的损伤,常见的肝损伤有化学性肝损伤、药物性肝损伤、免疫性肝损伤和酒精性肝损伤等。肝脏具有很强的再生能力,但是过度或持续的损伤会打破肝脏组织损伤与修复之间的平衡,使肝脏发生不可逆病变,导致肝纤维化、肝硬化甚至导致肝细胞癌等。因此预防和治疗肝损伤在肝脏疾病治疗过程当中具有重要意义,可有效减少肝纤维化、肝硬化或肝癌的发生。有研究表明,在我国,肝脏疾病发生率逐年升高并且呈低龄化发展态势。寻找治疗肝脏疾病的新思路、新方法迫在眉睫,而目前临床上具有的保肝药物及使用方法存在毒副作用,从而使保肝药物的使用受到限制。所以从传统天然药物中发现有效的新型保肝药物具有重要意义。
头花蓼(Polygonum capitatum Buch.-Ham.ex D.Don)是蓼科(Polygonaceae)蓼属(Polygonum)植物,药用部位为头花蓼的干燥全草或地上部分,又名四季红、石莽草、水绣球。头花蓼作为我国苗族民间常用药,其味苦、辛、性凉,归肾、膀胱经,具有清热利湿、解毒止痛、活血散瘀、利尿通淋之功效。头花蓼主要分布在贵州、云南等地,现代药理学研究表明其具有抗氧化、抗炎、抗菌、降糖、解热镇痛、调血脂等多种药理作用。其主要含黄酮类、酚酸类、木脂素类、烷基糖苷类、有机酸类、醇类、酯类、三萜类、鞣质类等多种化学成分。民间常用全草或地上部位治疗泌尿系统感染、血尿、湿疹、肾盂肾炎、膀胱炎、尿路结石、风湿痛、跌打损伤、疮疡、腹泻、痢疾等症。并且,目前尚未发现头花蓼提取物在保肝方面,尤其是针对急性肝损伤方面的应用和研究。
因此,从现有的传统天然药物中发现有效的新型保肝药物具有重要意义,是目前重要的研究方向。
发明内容
为了解决上述问题,本发明提供了具有抗急性肝损伤作用的头花蓼及其提取物,为治疗肝损伤,尤其是急性肝损伤提供了有效的药物,具体如下:
头花蓼在制备抗肝损伤药物方面的应用。
进一步的,所述制备抗肝损伤药物方面的应用,是制备用于治疗、预防、减轻、缓解与肝损伤有关的疾病的药物中的应用。
进一步的,所述抗肝损伤药物,是抗急性肝损伤的药物。
进一步的,所述抗肝损伤药物,是抗急性肝炎肝损伤的药物。
进一步的,所述抗肝损伤药物,是抗氧化性肝损伤的药物。
进一步的,所述抗肝损伤药物,是抗化学性肝损伤的药物。
进一步的,所述头花蓼,是头花蓼醇提取物。进一步的,是头花蓼95%乙醇回流提取物,并经真空冻干所得提取物粉末。
进一步的,所述头花蓼,是头花蓼的全草或地上部分。
四氯化碳(CCl4)是一种对肝细胞有严重毒性作用的化学物质,其导致肝损伤的作用机制复杂,有研究表明与氧化应激和脂质过氧化反应有关。CCl4在肝内经细胞色素P450酶代谢激活,产生三氯甲基自由基(CCl3·)和过氧化三氯甲基自由基(OOCCl3·),这些自由基可与肝细胞膜、内质网和线粒体上的磷脂分子发生共价结合,引发脂质过氧化反应损害膜的结构和功能,并通过抑制细胞膜及线粒体膜上钙泵的活性,使得Ca2+内流,导致肝细胞损伤,从而影响细胞正常的物质能量代谢。脂质过氧化的副产物能与细胞内正常的蛋白质和DNA发生结合,引起肝细胞的凋亡和坏死,具有肝毒性和致癌作用。除此之外,四氯化碳代谢产物还可以刺激肝脏枯否细胞(Kupffer cells),释放促炎性细胞因子,进一步加重肝脏的损伤。CCl4诱导的小鼠肝损伤模型在病理生理等方面与人类肝脏疾病相似,且易于复制,是理想的小鼠肝损伤模型,所以CCl4诱导的肝损伤模型被广泛用于保肝药物的研究。
水飞蓟素(silymarin)是指从菊科草本植物水飞蓟当中提取所得的一类多酚类黄酮,因其显著的保肝药理活性而被人们熟知,水飞蓟素被用于治疗肝损伤是美国最常用的肝脏疾病的植物疗法。除了保肝作用以外,水飞蓟素还具有清除活性氧、抗肿瘤、抗心血管疾病、保护脑缺血损伤等作用。水飞蓟素通过其抗过氧化特性,可以减轻脂质过氧化和自由基损伤的产生,并且在已经遭受损伤的肝细胞内,水飞蓟素能刺激蛋白质的合成并使磷脂代谢正常化。总之,水飞蓟素最大的贡献是对肝细胞膜有稳定作用。所以,基于水飞蓟素显著的保肝活性而选择其作为本实验的阳性对照药。
目前引起肝损伤的因素很多,主要包括药物(化疗药、解热镇痛药、抗病毒药等),大自然和人类工业生产过程中的化学物质(黄曲霉毒素、四氯化碳、二甲基甲酰胺等),病毒(甲型肝炎病毒、乙型肝炎病毒等)以及酒精等,还有部分肝脏损伤是由于其他疾病引起的并发症,例如高血脂引起的肝脏损伤并发症,不属于急性肝损伤范畴。在治疗及药物选择使用时,需要针对不同原因的肝损伤来选择不同的治疗方式。四氯化碳诱导引起的肝损伤属于化学性肝损伤,可直接导致肝细胞与肝组织损伤。其主要治疗方式有抑制炎症因子释放,减轻肝脏的损伤。本申请中的头花蓼提取物,可以有效显著降低TNF-α、IL-17与IL-1β炎症因子的表达,通过抑制TNF-α、IL-17与IL-1β的mRNA水平,从而发挥苗药头花蓼提取物的抗急性肝炎肝损伤作用。
此外,研究表明肝脏也是血脂代谢的主要器官,包括脂肪的消化、分解、合成和运输。正常情况下,肝脏含有大约5%的脂肪,当脂肪水平超过该水平时,便蓄积在肝细胞中,导致脂肪肝。其中,高血脂可能导致脂肪肝和肝脏组织损伤,其发生机制可能为持续性的高血脂会增加肝脏脂质代谢的负担,导致血脂在肝细胞聚集,从而引发脂肪肝。而脂肪肝则可以导致患者的ALT、AST等肝功能指标异常,其作用机制可能是通过激活过氧化物酶体增殖物激活受体(PPARs)通路,下调硬脂酸辅酶A脱氢酶1(SCD)和脂肪酸合成酶(FASN)mRNA的表达,进而降低肝细胞内甘油三酯的水平,从而改善肝损伤。
但是,高血脂不能直接导致肝损伤,高血脂引起肝损伤的主要原因是持续性的高血脂引起胆固醇和甘油三酯在肝脏中的蓄积作用,进而促进肝细胞脂肪变性,最终可能导致肝功能损伤。其主要治疗方法为,降低肝细胞中胆固醇、血脂与甘油三酯的水平。例如,使用黄酮类化合物,可以通过抑制脂肪酸合成途径中的一些关键因子的表达,进而抑制肝脏脂质积累。
与现有技术相比,本发明创造的技术效果体现在:
本发明提供了能够制备抗肝损伤药物的头花蓼提取物,对急性肝损伤具有明显的保护效果以及剂量依赖,有效的显著保护了四氯化碳造成的急性肝损伤。头花蓼醇提物能有效减轻肝细胞坏死程度,降低肝细胞炎症浸润程度,减少肝细胞空泡样变性,有明显保护肝损伤的效果。头花蓼醇提取物可通过抑制炎症因子TNF-α、IL-17与IL-1β的水平,从而发挥急性肝损伤保肝作用。头花蓼醇提取物能够用于制备抗肝损伤药物,为治疗急性肝炎肝损伤提供了全新的、安全有效的天然药物,可以得到一系列以其为基础的新型急性肝损伤保肝药物。
附图说明
图1头花蓼醇提取物是对由CCl4诱导引起的肝损伤的保护作用结果:(A)血生化指标AST和ALT值(***p<0.001,**p<0.01与模型组比较,###p<0.001与空白组比较)(B)在10×倍显微镜下的由CCl4诱导引起的肝损伤的小鼠肝脏病理切片图
图2是头花蓼醇提取物保肝作用TNF-α、IL-17与IL-1β基因转录水平(*p<0.05,***p<0.001与模型组比较,###p<0.001与空白组比较)
具体实施方式
下面结合具体的实施方式对本发明的技术方案做进一步的限定,但要求保护的范围不仅局限于所作的描述。
实施例
实施例1、头花蓼提取物的制备过程。
1、实验材料和方法。
提取物制备:将1000g的头花蓼粉碎干粉在95%乙醇中回流提取3次,每次2-3小时。滤液浓缩合并后,得到头花蓼醇提取物浸膏。并经真空冻干,得到头花蓼醇提取物粉末,置入干燥器中,备用。
2、实验结果。
头花蓼醇提取物粉末约200mg。
实施例2、头花蓼醇提物对四氯化碳造成的小鼠急性肝损伤的保护作用。
1、实验材料和方法。
4-6周雄性KM鼠购自贵州医科大学实验动物中心,给予12h光照12h黑暗,恒温,正常饲料及水饲养,于无菌环境中适应4天后进行实验。
动物随机分为5组(n=6),1)对照组及2)模型组动物每天按10mL/kg灌胃0.3%羧甲基纤维素钠溶液,3)阳性药组每天按10mL/kg灌胃10mg/mL的水飞蓟素混悬液(混于0.3%羧甲基纤维素钠溶液),4)头花蓼提取物低剂量保护组、5)头花蓼提取物高剂量保护组每天按10mL/kg分别灌胃50mg/mL、20mg/mL的苦参提取物混悬液(给药剂量500mg/kg、200mg/kg)。连续给药7天,第7天灌胃6h后,1)对照组腹腔注射玉米油(7mL/kg),2)~5)组腹腔注射CCl4造模(0.2%v/v,7ml/kg,溶于玉米油),24h后摘眼球取血,心脏灌流后取肝组织。血液样品室温静置2h后4℃8000g离心15min取血清。
血清样品进行血生化分析,检测ALT、AST指标(按说明书使用谷草转氨酶活力检测试剂盒及谷丙转氨酶活力检测试剂盒检测血生化指标谷草转氨酶(AST)和谷丙转氨酶(ALT))。肝脏组织经多聚甲醛固定后进行石蜡包埋、切片、HE染色、拍照。
2、实验结果。
实验数据计量资料均以均数±标准差表示,两均数的比较使用SPSS16.0统计软件中的one-wayANOVA分析,*p<0.05,**p<0.01,***p<0.001与模型组比较。
肝细胞受损后会释放谷丙转氨酶(ALT)和谷草转氨酶(AST),血清中的这些酶浓度反应肝损伤程度。如图1(A),血生化结果显示头花蓼提取物有明显的保护效果以及剂量依赖,显著保护了四氯化碳造成的急性肝损伤。
在光学显微镜下,无损伤的小鼠肝组织切片中,可见肝细胞大小、形态均正常,无肝实质性细胞病变,中央静脉及汇管区正常,如图1(B)所示。四氯化碳损伤后的模型组,小鼠肝组织中中央静脉周围肝细胞无正常细胞形态,肝细胞肿大,部分细胞呈气球样变性,有炎症细胞浸润现象。经给药头花蓼提取物后,肝细胞坏死程度显著减轻,炎症浸润程度降低,低剂量给药组部分细胞仍呈现气球样变性,高剂量给药组几乎无气球样变性。与血生化结果吻合,说明头花蓼提取物有明显保护肝损伤的效果。
实施例3、头花蓼醇提物治疗小鼠急性肝损伤的作用机制研究。
1、实验材料和方法。
总RNA提取:切取各动物肝脏组织5-10mg至1.5mL离心管,加入500μL的LysisBuffer。用电动匀浆机、组织破碎仪匀浆。室温静置5分钟,以充分裂解组织。加入100μL的氯仿,用手震荡混匀,室温静置3分钟。12000rpm,4℃离心2分钟,小心地吸取出上清,转移到新的1.5mL离心管中。向吸取的上清中加入等体积的无水乙醇充分混匀,加入离心柱,4000rpm,4℃离心1分钟。向RNA柱中加入500μL的Wash Buffer1,4000rpm,4℃离心1分钟,倒掉废液,将收集管倾斜倒扣在吸水纸上磕几下,将管口残留的液体吸干净。向RNA柱中加入500μL的Wash Buffer2,4000rpm,4℃离心1分钟,倒掉废液,将收集管管口残留的液体用吸水纸吸干净。将RNA柱放回收集管,12000rpm,4℃离心1分钟,以完全去除可能残留的WashBuffer。将离心柱取出,放进一个新的无RNA酶的1.5mL离心管中,开盖晾干2分钟。在RNA柱的膜中心部位加入20-50μL的Elution Buffer,室温静置2分钟。12000rpm,4℃离心1分钟。洗脱下来的RNA建议置于冰上,用分光光度计检测OD进行RNA定量。(A260/280在1.90-2.20之间均属正常)
反转:将RNA浓度调整为一致,10或20μL体系进行反转录,具体步骤按照TIANGEN反转录试剂盒说明进行操作。
实时定量PCR:QPCR引物信息如表1,按表2配置反应体系后按表6程序进行试试定量PCR实验,并收集处理数据。
表1 QPCR引物信息
Tab.1 Primer information of QPCR
表2 QPCR反应体系
Tab.2 The reaction system of QPCR
表3 QPCR反应程序
Tab.3 The response procedures of QPCR
2、实验结果。
结果显示,从图2可知,TNF-α、IL-17与IL-1β蛋白的mRNA转录水平在各组之间差异明显:模型组动物肝脏中炎症因子表达水平比空白组动物肝脏明显升高,说明CCl4造成的急性肝损伤导致肝脏中炎症相关因子表达显著升高,从而引起炎症、凋亡等一系列损伤反应。阳性药水飞蓟素组和头花蓼醇提物高剂量组动物肝脏中的TNF-α、IL-17与IL-1β显著下降(p<0.01),说明头花蓼醇提取物能够显著降低TNF-α、IL-17与IL-1β炎症因子的表达。通过抑制TNF-α、IL-17与IL-1β的mRNA水平,从而发挥苗药头花蓼提取物保肝的作用(图2)。初步表明头花蓼提取物对四氯化碳诱导的小鼠肝损伤具有显著的治疗作用。
最后,应当指出,以上实施例仅是本发明较有代表性的例子。显然,本发明的技术方案并不限于上述实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
Claims (9)
1.头花蓼在制备抗肝损伤药物方面的应用。
2.根据权利要求1所述的应用,其特征在于,所述制备抗肝损伤药物方面的应用,是制备用于治疗、预防、减轻、缓解与肝损伤有关的疾病的药物中的应用。
3.根据权利要求1所述的应用,其特征在于,所述抗肝损伤药物,是抗急性肝损伤的药物。
4.根据权利要求1所述的应用,其特征在于,所述抗肝损伤药物,是抗急性肝炎肝损伤的药物。
5.根据权利要求1所述的应用,其特征在于,所述抗肝损伤药物,是抗氧化性肝损伤的药物。
6.根据权利要求1所述的应用,其特征在于,所述抗肝损伤药物,是抗化学性肝损伤的药物。
7.根据权利要求1所述的应用,其特征在于,所述头花蓼,是头花蓼醇提取物。
8.根据权利要求7所述的应用,其特征在于,所述头花蓼醇提取物,是头花蓼95%乙醇回流提取物,并经真空冻干所得提取物粉末。
9.根据权利要求1所述的应用,其特征在于,所述头花蓼,是头花蓼的全草或地上部分。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210976424.6A CN115212254A (zh) | 2022-08-15 | 2022-08-15 | 头花蓼在制备抗肝损伤药物方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210976424.6A CN115212254A (zh) | 2022-08-15 | 2022-08-15 | 头花蓼在制备抗肝损伤药物方面的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115212254A true CN115212254A (zh) | 2022-10-21 |
Family
ID=83615506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210976424.6A Pending CN115212254A (zh) | 2022-08-15 | 2022-08-15 | 头花蓼在制备抗肝损伤药物方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115212254A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732421A (zh) * | 2010-01-04 | 2010-06-16 | 贵阳医学院 | 头花蓼总黄酮、总鞣质和没食子酸类化合物的制备方法 |
CN106389765A (zh) * | 2016-10-19 | 2017-02-15 | 南京康凯生物科技有限公司 | 一种解酒中药组合物及其制备方法 |
CN110368419A (zh) * | 2019-07-02 | 2019-10-25 | 贵州医科大学 | 头花蓼在调节尿酸方面的应用 |
-
2022
- 2022-08-15 CN CN202210976424.6A patent/CN115212254A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732421A (zh) * | 2010-01-04 | 2010-06-16 | 贵阳医学院 | 头花蓼总黄酮、总鞣质和没食子酸类化合物的制备方法 |
CN106389765A (zh) * | 2016-10-19 | 2017-02-15 | 南京康凯生物科技有限公司 | 一种解酒中药组合物及其制备方法 |
CN110368419A (zh) * | 2019-07-02 | 2019-10-25 | 贵州医科大学 | 头花蓼在调节尿酸方面的应用 |
Non-Patent Citations (2)
Title |
---|
廖莉玲,等: "头花蓼总黄酮纯化工艺的研究" * |
王智谦: "头花蓼中黄酮类化合物对大鼠血脂紊乱、肝损伤和动脉粥样硬化的保护" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009097512A1 (en) | Herbal pharmaceutical compositions to treat inflammation and inflammation associated conditions and diseases | |
CN104013668B (zh) | 甘草黄酮类提取物用于制备治疗溃疡性结肠炎药物中应用 | |
CN108888670B (zh) | 一种治疗溃疡性结肠炎的结肠靶向胶囊剂及其制备工艺 | |
Zhong et al. | Protective effect of total flavonoids from Bidens bipinnata L. against carbon tetrachloride‐induced liver injury in mice | |
CN103127273B (zh) | 一种治疗慢性肝病的复方药物及其制备方法 | |
CN104840695A (zh) | 一种用于治疗仔猪白痢的药物组合物及其制备方法 | |
KR100601390B1 (ko) | 혼합 생약재를 이용한 비만 억제용 조성물 | |
CN104435977B (zh) | 一种用于治疗肝损伤的药物及其制备方法 | |
CN101933973A (zh) | 防治肝损伤的药物组合物 | |
CN106421075A (zh) | 一种竹柳抗氧化活性组分的制备方法和应用 | |
CN115212254A (zh) | 头花蓼在制备抗肝损伤药物方面的应用 | |
CN103655544B (zh) | 棕矢车菊素在制备预防或治疗慢性肝损伤和肝纤维化的药物中的应用 | |
CN115414458A (zh) | 一种治疗乙型肝炎的中药组合物及其制备方法 | |
TWI334782B (en) | A pharmaceutical mixture for hepatitis treatment and its preparation method | |
CN104367612B (zh) | 一种狗蚁草提取物的应用 | |
CN115006494A (zh) | 一种显脉旋覆花复合解酒组合物、解酒护肝制剂及其应用 | |
CN102228666A (zh) | 来自松花粉与姜黄的组合物及其制备方法和在制备治疗炎症性肠病的药物中的应用 | |
CN105726624A (zh) | 一种治疗糖尿病的药物组合物 | |
CN105727251B (zh) | 一种治疗脂肪肝的药物组合物 | |
CN109157635B (zh) | 一种具有抗抑郁作用的忍冬藤复方及其制备方法和应用 | |
CN116687994B (zh) | 一种金银花在制备降低川乌毒性药物方面的用途 | |
CN116785385B (zh) | 一种用于防治病毒性呼吸道疾病的中药组合物 | |
CN101057906B (zh) | 一种治疗肝炎的中药组合物及其药物制剂以及其应用 | |
CN111298061B (zh) | 一种清热解毒、祛瘀散结的中药组合物及其制备方法 | |
Muchtaromah et al. | The Correlation of Pegagan and Beluntas Leaf Extract Co-Treatment on Liver Histological Alteration and Circulating Transaminase Enzyme Level |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221021 |